Cerevel set for Phase III as tavapadon meets in early Parkinson’s

Eleven months after Bain Capital and Pfizer formed Cerevel to house the pharma’s discontinued neuroscience pipeline, the biotech is sending its Parkinson’s disease program to Phase III on the strength of its Phase II readout in early stage PD.

Cerevel Therapeutics LLC said Monday that once daily tavapadon (formerly PF-06649751) met the primary endpoint of reducing motor symptoms, as well as a secondary, patient-reported outcome, in early stage Parkinson’s disease patients in the Phase II trial. ...